Top marks for transparency: UCB praised for reporting clinical research data
Posted by
24-Jan-2018
UCB has been recognised as a top performer for clinical data disclosure by a leading medical news agency.
Universities, research institutes and pharmaceutical companies are legally required to report clinical trial results to public databases. At UCB, we are working hard to be leaders in fostering transparency in our field for the benefit of patients.
One of the ways we do this is through the ClinicalTrials.gov website – a US federal database for registering clinical research studies and sharing study results. STAT News, a reputable news website focused on health and medical topics, analysed how research-performing organisations use the system.
A team of STAT News analysts examined more than 250,000 studies registered on ClinicalTrials.gov and excluded all studies that were not required by law to be reported. For the remaining ~18,700 studies, STAT rated the performance of organisations as to whether they had reported the information on time, every time.
UCB was highlighted for its exemplary approach to clinical trial reporting. “Stellar results came from a few drug companies, including Belgium-based UCB — the top performer of any leading organization,” according to STAT News. “It was among a handful of top research entities that posted all required trial results. And unlike most others, UCB did so within the legal time limit in the vast majority of cases.”
We are pleased to be recognised as one of a handful of research entities that reported all required trial results. As a global biopharmaceutical company focused on the development of innovative medicines, UCB supports responsible sharing of clinical study data. By doing this, we hope to support the generation of new scientific knowledge or insights, which ultimately benefit patients.
In the Clinical Studies section of our website, you can learn more about our approach to sharing results with patients who participate in our studies, enhancing public access to study information, and sharing data with researchers.
Universities, research institutes and pharmaceutical companies are legally required to report clinical trial results to public databases. At UCB, we are working hard to be leaders in fostering transparency in our field for the benefit of patients.
One of the ways we do this is through the ClinicalTrials.gov website – a US federal database for registering clinical research studies and sharing study results. STAT News, a reputable news website focused on health and medical topics, analysed how research-performing organisations use the system.
A team of STAT News analysts examined more than 250,000 studies registered on ClinicalTrials.gov and excluded all studies that were not required by law to be reported. For the remaining ~18,700 studies, STAT rated the performance of organisations as to whether they had reported the information on time, every time.
UCB was highlighted for its exemplary approach to clinical trial reporting. “Stellar results came from a few drug companies, including Belgium-based UCB — the top performer of any leading organization,” according to STAT News. “It was among a handful of top research entities that posted all required trial results. And unlike most others, UCB did so within the legal time limit in the vast majority of cases.”
We are pleased to be recognised as one of a handful of research entities that reported all required trial results. As a global biopharmaceutical company focused on the development of innovative medicines, UCB supports responsible sharing of clinical study data. By doing this, we hope to support the generation of new scientific knowledge or insights, which ultimately benefit patients.
In the Clinical Studies section of our website, you can learn more about our approach to sharing results with patients who participate in our studies, enhancing public access to study information, and sharing data with researchers.
Leave a Comment
Great blog related toclinical researh . very informative blog. I read all contents of this blog. all contents are very nice.after a long time i found your blog which have a good knowledge.nice and amazing post. I really appreciate you on good effort. keep sharing such great article.